Suggested remit To appraise the clinical and cost effectiveness of lumasiran within its marketing authorisation for treating primary hyperoxaluria type 1.
Status Proposed
Process STA 2018
ID number 3765

Provisional Schedule

Scoping workshop (Manchester) 24 July 2020 (14:00)

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
05 June 2020 - 03 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance